HER2 status best predicts benefit of anti-HER2 therapy
Read the full story on MD Consult: HER2 status best predicts benefit of anti-HER2 therapy (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - January 25, 2013 Category: Journals (General) Source Type: news

Synthon Biopharmaceuticals Reports Positive Early Results With Its Second Generation HER2-Antibody-Drug Conjugate
Best-in-Class potential with improved therapeutic index compared to other armed antibodies Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New Drug Target For Her-2 Related Breast Cancer
Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells. The inactivation of a tumor suppression gene called Nischarin is among the mechanisms identified. The findings provide a new therapeutic target to block the function of Her2. The research was published in Cancer Research, OnlineFirst. About 30% of breast cancers are positive for the Her2 oncogene... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients
(American Association for Cancer Research) Early use of PI3K inhibitors may prevent or delay treatment resistance. Cancer cells resistant to anti-HER2 therapy had high levels of survivin. Newly identified biomarker may help predict anti-HER2 therapy resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2013 Category: Global & Universal Source Type: news

Synthon reports positive pre-clinical results from HER2-antibody-drug conjugate studies
Synthon Biopharmaceuticals has reported positive early pre-clinical results of its second generation HER2-antibody-drug conjugate (ADC). (Source: Drug Development Technology)
Source: Drug Development Technology - January 23, 2013 Category: Pharmaceuticals Source Type: news

LSUHSC research provides new drug target for Her-2 related breast cancer
(Louisiana State University Health Sciences Center) Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells. The inactivation of a tumor suppression gene called Nischarin is among the mechanisms identified. The findings provide a new therapeutic target to block the function of Her2. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2013 Category: Global & Universal Source Type: news

TapImmune reports positive interim safety analysis in breast cancer study
Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens. (Source: Drug Development Technology)
Source: Drug Development Technology - January 11, 2013 Category: Pharmaceuticals Source Type: news

Bevacizumab plus paclitaxel vs. bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: phase III TURANDOT trial interim results
Source: Lancet Oncology Area: News Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine improves progression-free survival (PFS) and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. These two regimens were thus compared in an open-label, non-inferiority, phase III trial [TURANDOT (capeciTabine and bevacizumab Randomised Against avastiN anD taxOl Trial)].   The trial was designed to answer three main questions:   ...
Source: NeLM - News - January 10, 2013 Category: Drugs & Pharmacology Source Type: news

Direct Healthcare Professional Communication: Lapatinib combined with capecitabine has poorer efficacy compared with trastuzumab combined with capecitabine
Source: MHRA, GlaxoSmithKiline (GSK) Area: News GSK, in agreement with the European Medicines Agency and the MHRA has issued this communcation following the findings of two recent trials showing a statistically superior efficacy of trastuzumab- as compared with lapatinib-based regimens in certain settings. This effect was particularly pronounced in the patients who had no prior exposure to trastuzumab.   EGF111438/CEREBEL is a phase III trial comparing lapatinib in combination with capecitabine relative to trastuzumab in combination with capecitabine on the incidence of CNS as site of first relapse in women with ...
Source: NeLM - News - January 3, 2013 Category: Drugs & Pharmacology Source Type: news

Lapatinib benefits found for HER2-positive early-stage patients
Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology. (Source: MedWire News - Breast Cancer)
Source: MedWire News - Breast Cancer - December 17, 2012 Category: Cancer & Oncology Source Type: news

HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report
12/14/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2012 Category: Urology & Nephrology Source Type: news

NCCN Offers HER2 Testing for Breast Cancer Patients
Summary based on NCCN HER2 Testing Task Force Report JENKINTOWN, Pa., January 8, 2007 — The National Comprehensive Cancer Network (NCCN) and Research Advocacy Network have created an online report to educate breast cancer patients about the significance and importance of HER2 testing. Results of this test are essential in determining the correct treatment plan for breast cancer patients. Breast cancers can be categorized as HER2 positive or HER2 negative. HER2-positive breast cancer grows m... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 8, 2007 Category: Cancer & Oncology Source Type: news